bioAffinity Technologies, Inc.
BIAF · XNASCIK 1712762fmd_0439XRN1MY3PFHP4RPCKYSBRSJServices · Services-Commercial Physical & Biological ResearchTemplate: Standard
Coverage: Jan 01, 2021 to Sep 30, 2026, 22 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total revenues | – | 7 | 8 | 9 | 6 |
| Cost of revenue | – | 0 | – | – | – |
| Gross profit | – | 0 | – | – | – |
| Research and development | 1 | 1 | 1 | 1 | 1 |
| Selling, general and administrative | 1 | 2 | 7 | 10 | 10 |
| Total operating expenses | 2 | 4 | 11 | 18 | 17 |
| Operating income | (2) | (4) | (8) | (9) | (11) |
| Interest expense | 1 | 3 | 0 | 0 | 0 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | – | (4) | 0 | (0) | (4) |
| Income before taxes | (6) | (8) | (8) | (9) | (15) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (6) | (8) | (8) | (9) | (15) |
| Net income | (6) | (8) | (8) | (9) | (15) |